Tags » Nephrology

FDA allows marketing of the first test to assess risk of developing acute kidney injury

The U.S. Food and Drug Administration has allowed marketing of the NephroCheck test, a first-of-a-kind laboratory test to help determine if certain critically ill hospitalized patients are at risk of developing moderate to severe acute kidney injury (AKI) in the 12 hours following the administration of the test. 443 more words

IAHCP

FDA allows marketing of the first test to assess risk of developing acute kidney injury

The U.S. Food and Drug Administration has allowed marketing of the NephroCheck test, a first-of-a-kind laboratory test to help determine if certain critically ill hospitalized patients are at risk of developing moderate to severe acute kidney injury (AKI) in the 12 hours following the administration of the test. 443 more words

Gaylord T. Hoffert MD

FDA allows marketing of the first test to assess risk of developing acute kidney injury

The U.S. Food and Drug Administration has allowed marketing of the NephroCheck test, a first-of-a-kind laboratory test to help determine if certain critically ill hospitalized patients are at risk of developing moderate to severe acute kidney injury (AKI) in the 12 hours following the administration of the test. 443 more words

Dr. Albert M. DeFabritus

FDA allows marketing of the first test to assess risk of developing acute kidney injury

The U.S. Food and Drug Administration has allowed marketing of the NephroCheck test, a first-of-a-kind laboratory test to help determine if certain critically ill hospitalized patients are at risk of developing moderate to severe acute kidney injury (AKI) in the 12 hours following the administration of the test. 443 more words

Dr. Mark A. Perazella

FDA allows marketing of the first test to assess risk of developing acute kidney injury

The U.S. Food and Drug Administration has allowed marketing of the NephroCheck test, a first-of-a-kind laboratory test to help determine if certain critically ill hospitalized patients are at risk of developing moderate to severe acute kidney injury (AKI) in the 12 hours following the administration of the test. 443 more words

DR. Mohammad Zahid

FDA allows marketing of the first test to assess risk of developing acute kidney injury

The U.S. Food and Drug Administration has allowed marketing of the NephroCheck test, a first-of-a-kind laboratory test to help determine if certain critically ill hospitalized patients are at risk of developing moderate to severe acute kidney injury (AKI) in the 12 hours following the administration of the test. 443 more words

Dr. Ronald W. Hamner

FDA allows marketing of the first test to assess risk of developing acute kidney injury

The U.S. Food and Drug Administration has allowed marketing of the NephroCheck test, a first-of-a-kind laboratory test to help determine if certain critically ill hospitalized patients are at risk of developing moderate to severe acute kidney injury (AKI) in the 12 hours following the administration of the test. 443 more words

Dr. William M. Bennett